

When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?

In the January 2024 issue, the article by Badwan OZ, Braghieri L, Skoza W, Agrawal A, Menon V, Tang WHW. *When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?* *Cleve Clin J Med* 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034 contained an error in **Figure 1**. The dosage of empagliflozin was given as 10–25 mg twice daily. The correct dosage is 10–25 mg once daily. The corrected version appears below:




Figure 1. Proposed algorithm for initiating sodium-glucose cotransporter 2 inhibitors in acute decompensated heart failure.

^aDapagliflozin: No dosage adjustment for $\text{eGFR} \geq 25 \text{ mL/min/1.73 m}^2$. Manufacturer labeling does not recommend initiation of therapy at $\text{eGFR} < 25 \text{ mL/min/1.73 m}^2$. Sotagliflozin is not indicated for patients with $\text{eGFR} < 25 \text{ mL/min/1.73 m}^2$. For heart failure, empagliflozin is not indicated for $\text{eGFR} < 20 \text{ mL/min/1.73 m}^2$. For type 2 diabetes mellitus, empagliflozin is not indicated for $\text{eGFR} < 30 \text{ mL/min/1.73 m}^2$.

^bDirect evidence on the effects of canagliflozin and ertugliflozin on heart failure outcomes is available only in patients with type 2 diabetes mellitus. It remains to be determined if they have similar effects in patients without type 2 diabetes.

eGFR = estimated glomerular filtration rate; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SBP = systolic blood pressure; SGLT-2 = sodium-glucose cotransporter 2